NHS Framework Agreement for Branded Medicines in London and South of England

About

NHS England awarded a contract to Dr.

Reddy's Laboratories (UK) Limited, Accord-UK Ltd, Techdow Pharma England Ltd, UL Global Pharma, Biogen, Amgen Ltd, Thornton and Ross Ltd, Merck Sharpe & Dohme (UK) Limited, Bayer Ltd, and Zentiva Pharma UK Ltd for the supply of branded medicines under a framework agreement covering London and the South of England.

The agreement, valued at £558,521,926, includes multiple tranches with varying periods: London Tranche B and South of England Tranche A from 1 September 2021 to 31 August 2023, with extension options up to 24 months; London Annual Tranche, South of England Tranche B, and South of England Annual Tranche from 1 September 2021 to 31 August 2022, with extension options up to 12 months; and a Midlands & East and North of England Bevacizumab tranche from 1 September 2021 to 28 February 2022, with extension options up to 6 months.